Bright near-infrared-emitting AgS nanocrystals (NCs) are used for in vivo temperature sensing relying on a reversible variation in intensity and photoluminescence lifetime within the physiological temperature range. Here, to gain insights into the luminescence and quenching mechanisms, we investigated the temperature-dependent luminescence of AgS NCs from 300 to 10 K. Interestingly, both emission and lifetime measurements reveal similar and strong thermal quenching from 200 to 300 K, indicating an intrinsic quenching process that limits the photoluminescence quantum yield at room temperature, even for perfectly passivated NCs.
View Article and Find Full Text PDFThe upconversion luminescence (UCL) lifetime has a wide range of applications, serving as a critical parameter for optimizing the performance of upconversion nanoparticles (UCNPs) in various fields. It is crucial to understand that this lifetime does not directly correlate with the decay time of the emission level; rather, it represents a compilation of all the physical phenomena taking place in the upconversion process. To delve deeper into this, we analyzed the dependence of the UCL lifetime on the excitation pulse width for β-NaYF:Yb,Er nanoparticles.
View Article and Find Full Text PDFRev Alerg Mex
February 2024
Objective: To report the pollen as a new allergen capable of triggering allergic symptoms.
Methods: The pollen counts were made according to standardized technique with a Burkard seven days following the European Aerobiology Society´s Network Group recommendations.1 The trap was installed on the roof of Clinica SANNA, El Golf, San Isidro, which is 20 m high, 12°5'54"S 77°3'6"W in the west-south of the Lima urban area.
Background: Hereditary Angioedema (HAE) is a rare disease characterized by episodes of swelling, HAE crisis could cause death by suffocation, and also affect the quality of life in these patients. There exists an important disparity of HAE specific treatments between countries, inclusive in the same region, currently in Perú we use moderate and high doses of Tranexamic Acid (TA) in prophylaxis therapy and in acute HAE crisis respectively.
Objective: To report our experience with TA in three types of HAE patients and be a guide to other countries with this therapy, where HAE specific treatments are not registered.